SCHEMBL3687624

SCHEMBL3687624

CCCOCC(C)(C)C(=O)O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.37
CYP4F2 P78329 1/20 0.35
CYP4A11 Q02928 1/20 0.35
HSD17B10 Q99714 2/20 0.34
HCAR2 Q8TDS4 1/20 0.34
LMNA P02545 3/20 0.33
TSHR P16473 3/20 0.33
ALDH1A1 P00352 2/20 0.33
ACLY P53396 1/20 0.33
PPARA Q07869 3/20 0.33
THRB P10828 1/20 0.32
KDM4C Q9H3R0 1/20 0.32
ACACB O00763 1/20 0.32
ACACA Q13085 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C19 P33261 1/20 0.32
HIF1A Q16665 1/20 0.32
CES2 O00748 1/20 0.31
CES1 P23141 1/20 0.31
TTR P02766 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5852063 0.86 TSHR (0.43) CYP4F2CYP4A11HCAR2TSHRALDH1A1
SCHEMBL3807287 0.85 CES2 (0.48) CYP4F2CYP4A11HCAR2THRBCES2
SCHEMBL16174063 0.83 TSHR (0.45) CYP4F2CYP4A11HCAR2TSHRALDH1A1
SCHEMBL8052693 0.82 CYP2C9 (0.42) CYP2C9CYP4F2CYP4A11TSHRALDH1A1
SCHEMBL7711189 0.81 HSD17B10 (0.34) HSD17B10HCAR2LMNAALDH1A1THRB
SCHEMBL7632628 0.81 TSHR (0.41) CYP2C9CYP4F2CYP4A11TSHRALDH1A1
SCHEMBL4961008 0.80 CYP2C9 (0.39) CYP2C9CYP4F2CYP4A11HSD17B10LMNA
SCHEMBL2562954 0.79 CYP2C9 (0.36) CYP2C9CYP4F2CYP4A11HSD17B10LMNA
SCHEMBL3687804 0.79 CYP2C9 (0.36) CYP2C9CYP4F2CYP4A11TSHRALDH1A1
Ammonia Solution, Strong SCHEMBL11068438 0.78 CYP2C9 (0.38) CYP2C9CYP4F2CYP4A11HSD17B10LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1417287-B1 NOVEL COMPOSITIONS CONTAINING ACETOXYLATED FATTY ACIDS OR FATTY ACID DERIVATES, IN PARTICULAR LUBRICANT AND PRESSURE TRANSMITTING COMPOSITIONS, THE PREPARATION AND USE THEREOF FUCHS PETROLUB AG (DE) 2012-12-12 EP claimed
US-7101831-B2 Compositions of material, especially lubricants and pressure transmitting means, the production and use thereof FUCHS PETROLUB AG (DE) 2006-09-05 US claimed
US-20030186823-A1 Novel compositions of material, especially lubricants and pressure transmitting means, the production and use thereof FUCHS PETROLUB SE (DE) 2003-10-02 US claimed
US-20130131052-A1 Amelioration Of The Development Of Cataracts And Other Ophthalmic Diseases MATIER WILLIAM L (US) 2013-05-23 US disclosed
US-20130131052-A1 Amelioration Of The Development Of Cataracts And Other Ophthalmic Diseases MATIER WILLIAM L (US) 2013-05-23 US disclosed
US-8383648-B2 Applying such as 1-oxyl-4-(3'-ethoxy-2',2'-dimethyl)propanecarbonyloxy-2,2,6,6-tetramethylpiperidine to eye surface; halting growth, preventing surgery COLBY PHARMACEUTICAL COMPANY (US) 2013-02-26 US disclosed
US-8383648-B2 Applying such as 1-oxyl-4-(3'-ethoxy-2',2'-dimethyl)propanecarbonyloxy-2,2,6,6-tetramethylpiperidine to eye surface; halting growth, preventing surgery COLBY PHARMACEUTICAL COMPANY (US) 2013-02-26 US disclosed
US-8383648-B2 Applying such as 1-oxyl-4-(3'-ethoxy-2',2'-dimethyl)propanecarbonyloxy-2,2,6,6-tetramethylpiperidine to eye surface; halting growth, preventing surgery COLBY PHARMACEUTICAL COMPANY (US) 2013-02-26 US disclosed
EP-1417287-B1 NOVEL COMPOSITIONS CONTAINING ACETOXYLATED FATTY ACIDS OR FATTY ACID DERIVATES, IN PARTICULAR LUBRICANT AND PRESSURE TRANSMITTING COMPOSITIONS, THE PREPARATION AND USE THEREOF FUCHS PETROLUB AG (DE) 2012-12-12 EP disclosed
US-7825134-B2 Amelioration of cataracts, macular degeneration and other ophthalmic diseases OTHERA HOLDING, INC. (US) 2010-11-02 US disclosed
US-7825134-B2 Amelioration of cataracts, macular degeneration and other ophthalmic diseases OTHERA HOLDING, INC. (US) 2010-11-02 US disclosed
US-7442711-B2 Amelioration of the development of cataracts and other ophthalmic diseases OTHERA HOLDING, INC. (US) 2008-10-28 US disclosed
US-7101831-B2 Compositions of material, especially lubricants and pressure transmitting means, the production and use thereof FUCHS PETROLUB AG (DE) 2006-09-05 US disclosed
US-20050131025-A1 Amelioration of cataracts, macular degeneration and other ophthalmic diseases COLBY PHARMACEUTICAL COMPANY 2005-06-16 US disclosed
EP-1417287-A1 NOVEL COMPOSITIONS CONTAINING ACETOXYLATED FATTY ACIDS OR FATTY ACID DERIVATES, IN PARTICUALR LUBRICANT AND PRESSURE TRANSMITTING COMPOSITIONS, THE PREPARATION AND USE THEREOF Fuchs Petrolub AG (DE) 2004-05-12 EP disclosed
US-20030186823-A1 Novel compositions of material, especially lubricants and pressure transmitting means, the production and use thereof FUCHS PETROLUB SE (DE) 2003-10-02 US disclosed
WO-2001053438-A1 NOVEL COMPOSITIONS OF MATERIAL, ESPECIALLY LUBRICANTS AND PRESSURE TRANSMITTING MEANS, THE PRODUCTION AND USE THEREOF FUCHS PETROLUB AG (DE) 2001-07-26 WO disclosed
EP-0129774-B1 PROCESS FOR THE PREPARATION OF ALDOLS BASF Aktiengesellschaft (DE) 1986-09-10 EP disclosed
US-4552985-A Preparation of aldols BASF AKTIENGESELLSCHAFT (DE) 1985-11-12 US disclosed
EP-0129774-A1 Process for the preparation of aldols BASF Aktiengesellschaft (DE) 1985-01-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030186823-A1 Novel compositions of material, especially lubricants and pressure transmitting means, the production and use thereof SLC27A2, SLC27A1, ELOVL1 CYP2C9 2227/4885CYP4F2 1681/4885CYP4A11 1314/4885
US-20130131052-A1 Amelioration Of The Development Of Cataracts And Other Ophthalmic Diseases C3AR1, C1R, AKR1C3 CYP2C9 1154/4885CYP4F2 1332/4885CYP4A11 174/4885
US-20050131025-A1 Amelioration of cataracts, macular degeneration and other ophthalmic diseases C1R, CRYAB, C9 CYP2C9 2207/4885CYP4F2 2422/4885CYP4A11 354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.